Monopotassium aspartate
CAS 1115-63-5
Monopotassium aspartate (CAS 1115-63-5) is a pharmaceutical compound with 0 bioactivity targets and 1,417 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Monopotassium aspartate is linked to DTXSID70273966 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Monopotassium aspartate used for in pharmaceutical contexts?
Monopotassium aspartate (CAS 1115-63-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Monopotassium aspartate?
Monopotassium aspartate has 1,417 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal discomfort, Abdominal distension, Abdominal pain, Abdominal pain upper, Accidental overdose. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Monopotassium aspartate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Potassium Aspartate with EU status "permitted".
What clinical phase is Monopotassium aspartate in?
No phase 1-4 clinical development badge is rendered for Monopotassium aspartate because the matched compound identifier rows do not contain a max-phase value.